26 October 2023 – 1 mins read
Ipsen delivers solid sales growth in the first nine months of 2023 and confirms its full-year guidance
Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical company, today presents its sales performance for the year to date and the third quarter of 2023.
Showing: 1 – 05 of 23 Financial Results
Ipsen reports strong first quarter 2018 sales growth of 23.1% at constant exchange rates
First quarter 2018 unaudited IFRS consolidated sales